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Summary Restricted expression of oncofetal fibronectin mRNA in the tissues of thyroid papillary and anaplastic carcinoma has recently been
shown by both Northern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR). Oncofetal fibronectin mRNA can be a
target of gene diagnosis and targeted gene therapy, provided it is expressed in all cancer cells in the tissues. To investigate this criterion in
thyroid cancer tissues, we measured their expression of oncofetal fibronectin mRNA using in situ hybridization. An abundant expression of
oncofetal fibronectin mRNA was found in all the observed cancer cells of six papillary carcinomas and an anaplastic carcinoma, but not in the
tissues of normal thyroid, Graves' disease, adenomatous goitre, follicular adenoma, follicular carcinoma or medullary carcinoma. This result
encourages us to establish gene diagnosis of thyroid papillary and anaplastic carcinomas by detecting oncofetal fibronectin mRNA in
biopsies.
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We have recently developed a modified method of differential
display (sequence-specific differential display, SS-DD) to screen
specific mRNAs expressed in cancer tissues, and succeeded in
finding several mRNAs the expression of which is restricted in
cancer tissues (Takano et al, 1997a). This discovery of mRNAs
exclusively expressed in cancer tissues is important for the field of
gene diagnosis and other cancer treatment technologies.
One such gene was oncofetal fibronectin. Fibronectins are high-
molecular-mass adhesive glycoproteins present in the extracellular
matrix and in body fluids (Yamada and Weston, 1974), and
oncofetal fibronectin is characterized by the presence of the
oncofetal domain, which is absent in normal fibronectin. The
oncofetal domain is recognized by a monoclonal antibody called
FDC-6 (Matsuura and Hakomori, 1985), and many researchers
have used this antibody to report the existence of oncofetal
fibronectin in malignant tissues such as breast, colon and gastric
cancers (Loridon-Rosa et al, 1990; David et al, 1993; Inufusa et al,
1995). We studied the expression of oncofetal fibronectin mRNA
in a total of98 thyroid tissues by reverse transcriptase polymerase
chain reaction (RT-PCR), and found that it is abundantly expressed
in all papillary and anaplastic carcinomas but not in normal
thyroid tissues, follicular adenomas or follicular carcinomas
(Takano et al, 1997a). Thus, oncofetal fibronectin is considered to
be an ideal target ofall genes currently known, both for gene diag-
nosis and for therapy of papillary and anaplastic carcinoma. It
remains to be shown, however, if all the cancer cells in the tissues
ofthese carcinomas express oncofetal fibronectin mRNA.
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We previously established a method named aspiration biopsy
RT-PCR (ABRP) to perform RT-PCR analysis of thyroid tumours
without any additional invasions by extracting RNA from the left-
over cells within the needles used for fine-needle aspiration biop-
sies (FNABs) (Takano et al, 1997b). Oncofetal fibronectin mRNA
is one of the preferable targets ofthis method but, before applying
it for clinical use, the expression of oncofetal fibronectin mRNA
in the majority of papillary and anaplastic cancer cells must be
confirmed. Further, the possibility of the focal expression of
oncofetal fibronectin mRNA in other tissues must be excluded.
Accordingly, we here studied the expression of oncofetal
fibronectin mRNA in 24 benign and malignant thyroid tissues
using in situ hybridization analysis, and confirm its restricted
expression in papillary and anaplastic carcinomas.
SUBJECTS AND METHODS
Subjects
Thyroid tumours were classified according to the WHO histolog-
ical classification ofthyroid tumours (Hedinger et al, 1989). Three
normal thyroid tissues, three tissues from patients with Graves'
disease, six papillary carcinomas, five follicular adenomas, one
follicular carcinoma, three adenomatous goitres, two medullary
carcinomas and one anaplastic carcinoma were subjected to in situ
hybridization. The fresh tissues were obtained at surgery and
immediately frozen in liquid nitrogen. Sections of 7-,um thickness
were cut on a cryostat, thaw-mounted on poly-L-lysine-coated
slides, and stored at -80 °C until use.
Methods
In situ hybridization was performed essentially as described by
Hirota et al (1992). Briefly, frozen sections were fixed with 4%
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Table 1 Expression of oncofetal fibronectin (oncFN) mRNA in thyroid
tumours
Tissue Total number oncFN mRNA(+) oncFN mRNA(-)
Normal thyroid 3 0 3
Adenomatous goitre 3 0 3
Follicular adenoma 5 0 5
Follicular carcinoma 1 0 1
Papillary carcinoma 6 6 0
Anaplastic carcinoma 1 1 0
Medullary carcinoma 2 0 2
Graves' disease 3 0 3
paraformaldehyde in 0.1 M phosphate buffer (PB) for 20 min.
They were then treated with 0.2 N hydrochloric acid for inactiva-
tion of internal alkaline phosphatase and acetylated with 0.25%
acetic anhydride in 0.1 M triethanolamine pH 8.0 for 10 min. After
acetylation, they were dehydrated with ethanol series and air dried.
The hybridization solution contained 50% deionized formamide,
10% dextran sulphate, 1 x Denhardt's solution, 600 mm sodium
chloride, 10 mM dithiothreitol (DTT), 0.25% sodium dodecyl
sulphate (SDS), 150 jig ml-1 of Escherichia coli tRNA and
approximately 0.5,g ml RNA probe. Digoxigenin-labelled
single-strand RNA probes were prepared using DIG RNA
labelling Kit (Boehringer Mannheim, Mannheim, Germany)
according to the manufacturer's instructions. For the generation of
the sense and antisense probes of the III CS sequence, a sequence
of human fibronectin cDNA (base 5889-6148) (Kornblihtt et al,
1985) obtained from a papillary carcinoma was subcloned into
pGEM plasmid (Promega, Madison, WI, USA). A 50-,ul aliquot of
hybridization solution was placed on each section, and the sections
were covered with siliconized coverglass and incubated at 50°C
for 16 h in a moisture chamber. After hybridization, the slides
were washed in 5 x SSC (1 x SSC = 0.15 M sodium chloride,
0.015 M sodium citrate) briefly and in 50% formamide, 2 x SSC
for 30 min at 50°C. RNase A (Wako, Osaka, Japan) treatment
(10 jig ml') was carried out at 37°C for 30 min. The slides were
treated twice with 2 x SSC and 0.2 x SSC for 15 min at 50°C.
Hybridized digoxigenin-labelled probes were detected using a
nucleic acid detection kit (Boehringer Mannheim, Mannheim,
Germany) according to the manufacturer's instructions. Controls
included (a) hybridization with the sense (mRNA) probe; (b)
RNase A treatment (20 ,ug ml') before hybridization; and (c) use
of either antisense RNA probe or anti-digoxigenin antibody. No
positive signals were seen in any of these three experiments.
RESULTS
Results are summarized in Table 1. Among 24 tissues examined,
all of six papillary carcinomas and one anaplastic carcinoma
showed positive staining for oncofetal fibronectin mRNA (Figure
1). In contrast, all the other tissues including the normal thyroid
tissues showed negative staining because the signal was the
same as that of the conrols described in Methods. The expression
level of oncofetal fibronectin mRNA varies substantially among
the cells in the anaplastic carcinoma, but no cell was observed
that did not express oncofetal fibronectin mRNA. Oncofetal
fibronectin mRNA was expressed in particular abundance in
the apical pole of papillary and follicular structures of papillary
carcinomas.
DISCUSSION
The expression of oncofetal fibronectin has been reported in
several kinds of malignant tissues, although usually via immuno-
histochemistry with FDC-6 (Loridon-Rosa et al, 1990; David et al,
1993; Inufusa et al, 1995). Restricted expression of oncofetal
fibronectin mRNA in papillary and anaplastic carcinomas was
previously confirmed by Northern blotting and RT-PCR, and in
this study its expression was found in all cancer cells in these
tissues but not in other tissues, including normal thyroid.
Morphologically, papillary carcinomas are known to be distin-
guished easily from follicular tumours, even ifthey are very small.
These results suggest distinct differences between the biological
features ofpapillary carcinoma cells and those ofthyroid follicular
tumour cells, differences that probably stem from the very begin-
ning of the cancer development.
No region showed positive staining of oncofetal fibronectin
mRNA in normal thyroid tissue. In the stomach, oncofetal
fibronectin is reported to exist not only in malignant tumours but
also in benign regenerative regions (David et al, 1993). Previous
reports show very low proliferative activity in the thyroid (Katoh
et al, 1995), which suggests the much rarer existence of the cells
possessing the proliferative ability in the thyroid tissue in compar-
ison with the stomach. This may be the cause of the discrepant
results in these two tissues.
Further, these results are of importance for the use of oncofetal
fibronectin mRNA expression as a target in gene diagnosis of
papillary and anaplastic carcinomas using RT-PCR as false nega-
tive results are not expected to occur frequently when the majority
of the cancer cells express this mRNA. Papillary and anaplastic
carcinomas might be accurately diagnosed using RT-PCR analysis
such as ABRP by using mRNA extracted from fine-needle
biopsies ofthyroid tumours.
This is the first report on oncofetal fibronectin expression in
thyroid medullary carcinomas. After examination of two
medullary carcinomas using in situ hybridization, we concluded
that oncofetal fibronectin was not expressed by either. Additional
examination using six medullary carcinomas using RT-PCR
corroborated this finding (data not shown).
It is interesting that all the cancer cells in an anaplastic carcinoma
express oncofetal fibronectin mRNA, given the distinct morpho-
logical differences between these cells. The expression of oncofetal
fibronectin might be vital for the survival and progression of
anaplastic carcinoma cells; thus, further studies are needed to clarify
the biological effects of the expression of the oncofetal domain on
anaplastic carcinomas. The expression of oncofetal fibronectin
mRNA, however, may not be closely related to the aggressive
features of anaplastic carcinomas because papillary carcinomas,
which show low clinical malignant grade, also express it.
According to these results, a new classification of thyroid
tumours may be established. Tumours ofthyroid epithelial descent
can be classified into two types: one expresses oncofetal
fibronectin mRNA and the other does not. Papillary and anaplastic
carcinoma are of the former type and follicular adenoma and
carcinoma of the latter type. Also, the expression of oncofetal
fibronectin mRNA can be used as a criterion in the diagnosis of
papillary carcinoma, and papillary carcinomas may be more
correctly diagnosed by the in situ hybridization method used in
this study. Finally, it will be interesting to investigate into which
group some variant tumours, such as the follicular variant of
papillary carcinoma, are classified (Tielens et al, 1994).
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Figure 1 Expression of oncofetal fibronectin mRNA in a normal thyroid tissue (A), an adenomatous goitre (B), a follicular adenoma (C), a follicular carcinoma
(D), papillary carcinomas (E and F), an anaplastic carcinoma (G) and a medullary carcinoma (H) (A, B, C, D and H, x 150; E, F and G, x400). A, B, C, D and H
were taken with high contrast to show tissue morphology otherwise scarcely visible
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